Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Rivaroxaban | hsa00500 | Starch and sucrose metabolism | 1.25E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Rivaroxaban | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Rivaroxaban | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Rivaroxaban | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Rivaroxaban | hsa00600 | Sphingolipid metabolism | 2.44E-02 | 2 | Q9BX95, Q06136 | SGPP1, FVT1 | More | | Rivaroxaban | hsa00730 | Thiamine metabolism | 2.32E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Rivaroxaban | hsa00785 | Lipoic acid metabolism | 4.32E-02 | 1 | Q9Y234 | LIPT1 | More | | Rivaroxaban | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | | Rivaroxaban | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Rivaroxaban | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Rivaroxaban | hsa03040 | Spliceosome | 1.26E-02 | 6 | P17844, P51991, P61978, Q15365, Q01130, P11142 | DDX5, HNRPA3, HNRPK, PCBP1, SFRS2, HSPA8 | More | | Rivaroxaban | hsa03060 | Protein export | 3.37E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | Rivaroxaban | hsa03450 | Non-homologous end-joining | 3.17E-03 | 2 | Q9NP87, P13010 | POLM, XRCC5 | More | | Rivaroxaban | hsa04064 | NF-kappa B signaling pathway | 2.69E-02 | 9 | P10415, O00463, P01375, Q04759, Q13077, Q16548, Q8WV28, P24522, P09341 | BCL2, TRAF5, TNF, PRKCQ, TRAF1, BCL2A1, BLNK, GADD45A, CXCL1 | More | | Rivaroxaban | hsa04071 | Sphingolipid signaling pathway | 2.06E-02 | 7 | Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415, Q9UQC2 | EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2, GAB2 | More | | Rivaroxaban | hsa04080 | Neuroactive ligand-receptor interaction | 2.54E-02 | 7 | P08311, Q15722, Q9H228, P21462, P21730, Q16581, P35318 | CTSG, LTB4R, EDG8, FPR1, C5AR1, C3AR1, ADM | More | | Rivaroxaban | hsa04141 | Protein processing in endoplasmic reticulum | 6.04E-03 | 8 | P18848, Q15437, Q99941, O75460, P11142, Q9H3Z4, P07900, Q9NR31 | ATF4, SEC23B, CREBL1, ERN1, HSPA8, DNAJC5, HSP90AA1, SAR1A | More | | Rivaroxaban | hsa04151 | PI3K-Akt signaling pathway | 9.80E-03 | 10 | O43521, P27348, Q13362, P07900, P22105, P23458, Q99941, P18848, O00141, Q6ZUJ8 | BCL2L11, YWHAQ, PPP2R5C, HSP90AA1, TNXB, JAK1, CREBL1, ATF4, SGK, PIK3AP1 | More | | Rivaroxaban | hsa04211 | Longevity regulating pathway | 4.57E-02 | 4 | P51828, Q99941, P18848, Q96RR4 | ADCY7, CREBL1, ATF4, CAMKK2 | More | | Rivaroxaban | hsa04217 | Necroptosis | 3.22E-04 | 11 | P01568, P23458, Q13489, Q9NQC7, Q13546, P07900, P05141, P01584, Q6FI13, Q9H444, O75351 | IFNA21, JAK1, BIRC3, CYLD, RIPK1, HSP90AA1, SLC25A5, IL1B, H2AC18; H2AC19, CHMP4B, VPS4B | More | | Rivaroxaban | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.26E-02 | 6 | P67936, P51828, Q99941, P18848, Q13362, P23634 | TPM4, ADCY7, CREBL1, ATF4, PPP2R5C, ATP2B4 | More | | Rivaroxaban | hsa04340 | Hedgehog signaling pathway | 1.43E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Rivaroxaban | hsa04390 | Hippo signaling pathway | 5.79E-03 | 4 | P04628, Q9UJU2, O43623, Q13489 | WNT1, LEF1, SNAI2, BIRC3 | More | | Rivaroxaban | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Rivaroxaban | hsa04610 | Complement and coagulation cascades | 3.16E-03 | 2 | P00734, P0C0L4 | F2, C4A | More | | Rivaroxaban | hsa04613 | Neutrophil extracellular trap formation | 1.93E-03 | 16 | O60603, P05164, P08246, Q9UM07, Q93077, P62807, O60814, P68431, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Rivaroxaban | hsa04621 | NOD-like receptor signaling pathway | 2.35E-03 | 14 | P01584, P07900, Q16539, Q14643, P23458, Q9H3M7, P10599, Q9H1Y0, P43490, O00463, P10415, P01375, P09341, P12838 | IL1B, HSP90AA1, MAPK14, ITPR1, JAK1, TXNIP, TXN, ATG5, PBEF1, TRAF5, BCL2, TNF, CXCL1, DEFA4 | More | | Rivaroxaban | hsa04623 | Cytosolic DNA-sensing pathway | 5.29E-03 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | Rivaroxaban | hsa04650 | Natural killer cell mediated cytotoxicity | 4.40E-02 | 6 | P78314, P06239, O60880, P20963, P26718, O75015 | SH3BP2, LCK, SH2D1A, CD247, KLRK1, FCGR3B | More | | Rivaroxaban | hsa04657 | IL-17 signaling pathway | 1.28E-02 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | | Rivaroxaban | hsa04658 | Th1 and Th2 cell differentiation | 9.89E-05 | 10 | Q04759, P20963, P09693, Q16539, P06239, Q14765, P42226, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, MAPK14, LCK, STAT4, STAT6, GATA3, TBX21, HLA-DOB | More | | Rivaroxaban | hsa04659 | Th17 cell differentiation | 9.26E-04 | 10 | Q04759, Q16539, P06239, P42226, P13765, P14778, Q9UL17, P23771, P09693, P20963 | PRKCQ, MAPK14, LCK, STAT6, HLA-DOB, IL1R1, TBX21, GATA3, CD3G, CD247 | More | | Rivaroxaban | hsa04660 | T cell receptor signaling pathway | 1.07E-02 | 9 | P01375, Q04759, O95267, Q08881, P20963, P09693, P01732, Q16539, P49841 | TNF, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, MAPK14, GSK3B | More | | Rivaroxaban | hsa04911 | Insulin secretion | 4.85E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Rivaroxaban | hsa04915 | Estrogen signaling pathway | 1.65E-02 | 6 | Q99941, P18848, P51828, P07900, P11142, Q15788 | CREBL1, ATF4, ADCY7, HSP90AA1, HSPA8, NCOA1 | More | | Rivaroxaban | hsa04918 | Thyroid hormone synthesis | 2.50E-02 | 4 | P51828, Q99941, P18848, P05543 | ADCY7, CREBL1, ATF4, SERPINA7 | More | | Rivaroxaban | hsa04925 | Aldosterone synthesis and secretion | 2.50E-02 | 4 | Q99941, P18848, P51828, P23634 | CREBL1, ATF4, ADCY7, ATP2B4 | More | | Rivaroxaban | hsa04927 | Cortisol synthesis and secretion | 3.29E-02 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | | Rivaroxaban | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Rivaroxaban | hsa05132 | Salmonella infection | 1.67E-03 | 6 | Q9UJU2, Q13546, Q13489, Q13561, Q13509, P68371 | LEF1, RIPK1, BIRC3, DCTN2, TUBB3, TUBB2C | More | | Rivaroxaban | hsa05133 | Pertussis | 2.24E-02 | 2 | P0DP23, P0C0L4 | CALM1, C4A | More | | Rivaroxaban | hsa05143 | African trypanosomiasis | 4.81E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Rivaroxaban | hsa05144 | Malaria | 1.44E-02 | 4 | P60033, O60603, P35443, P26718 | CD81, TLR2, THBS4, KLRK1 | More | | Rivaroxaban | hsa05150 | Staphylococcus aureus infection | 4.37E-02 | 6 | P21730, P21462, O75015, P13765, Q16581, P12838 | C5AR1, FPR1, FCGR3B, HLA-DOB, C3AR1, DEFA4 | More | | Rivaroxaban | hsa05163 | Human cytomegalovirus infection | 4.52E-02 | 7 | P51828, P23458, P01584, P61073, Q13651, Q99941, P18848 | ADCY7, JAK1, IL1B, CXCR4, IL10RA, CREBL1, ATF4 | More | | Rivaroxaban | hsa05169 | Epstein-Barr virus infection | 5.92E-03 | 12 | P13765, Q13547, O00463, P16070, P10415, Q16539, P24522, Q8WV28, P01375, O60603, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, CD44, BCL2, MAPK14, GADD45A, BLNK, TNF, TLR2, CD3G, CD247 | More | | Rivaroxaban | hsa05202 | Transcriptional misregulation in cancer | 8.07E-04 | 14 | Q15532, P14780, P27930, Q16548, Q13077, Q15652, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P24522 | SS18, MMP9, IL1R2, BCL2A1, TRAF1, JMJD1C, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, GADD45A | More | | Rivaroxaban | hsa05203 | Viral carcinogenesis | 4.22E-03 | 9 | Q99941, P18848, P23458, P27348, Q7KZF4, Q15283, P61978, P62807, O60814 | CREBL1, ATF4, JAK1, YWHAQ, SND1, RASA2, HNRPK, HIST1H2BC, H2BC12 | More | | Rivaroxaban | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Rivaroxaban | hsa05217 | Basal cell carcinoma | 2.53E-03 | 5 | Q13635, P04628, P49841, Q9UJU2, P24522 | PTCH1, WNT1, GSK3B, LEF1, GADD45A | More | | Rivaroxaban | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.03E-02 | 5 | P20963, P09693, P06239, O60603, Q16539 | CD247, CD3G, LCK, TLR2, MAPK14 | More | | Rivaroxaban | hsa05321 | Inflammatory bowel disease | 7.62E-04 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P42226, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, STAT6, GATA3 | More | | Rivaroxaban | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | |